Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients

Summary Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF). Corticosteroids are used as first‐line therapy, but relapse and adverse effects commonly occur. Case reports have suggested the efficacy of the anti‐IgE recombinant humanized monoclonal an...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pediatric pulmonology Ročník 52; číslo 2; s. 190 - 197
Hlavní autori:	Nové‐Josserand, Raphaële, Grard, Soazic, Auzou, Lila, Reix, Philippe, Murris‐Espin, Marlène, Brémont, François, Mammar, Benyebka, Mely, Laurent, Hubert, Dominique, Durieu, Isabelle, Burgel, Pierre‐Régis
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 01.02.2017
Predmet:	Adolescent Adrenal Cortex Hormones - therapeutic use Adult allergic bronchopulmonary aspergillosis (ABPA) Anti-Allergic Agents - therapeutic use Antifungal Agents - therapeutic use Aspergillosis, Allergic Bronchopulmonary - complications Aspergillosis, Allergic Bronchopulmonary - drug therapy Aspergillosis, Allergic Bronchopulmonary - immunology Aspergillus fumigatus Child corticosteroids cystic fibrosis Cystic Fibrosis - complications Drug Therapy, Combination Female Humans IgE immunoglobulin E Immunoglobulin E - immunology Male Middle Aged Omalizumab - therapeutic use Retrospective Studies Young Adult corticosteroids Aspergillus fumigatus allergic bronchopulmonary aspergillosis (ABPA) immunoglobulin E IgE cystic fibrosis
ISSN:	8755-6863, 1099-0496, 1099-0496
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!